RxDoctor Payments Data

David Wild, MD

Cardiovascular Disease · Teaneck, NJNPI 1013112671

Payments from drug & device makers

$4,503in general payments, 2019–2025

Across 260 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$749
  • Novartis$596
  • Johnson & Johnson$377
  • Amgen$375
  • Merck$339
  • AstraZeneca$312
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,40298%
  • Education$1022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,503 in reported general payments places this provider in the 60th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$344,883
Medicare patients
2,393
Services billed
4,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban307$332,484
XareltoRivaroxaban79$78,124
EntrestoSacubitril/Valsartan63$66,037
Repatha SureclickEvolocumab14$18,653
Rosuvastatin Calcium281$5,491
Amlodipine Besylate480$4,906
Atorvastatin Calcium365$4,599
Valsartan69$4,280
Metoprolol Succinate310$3,545
Amiodarone Hcl46$2,371
Nebivolol Hcl34$2,363
Diltiazem 24hr Er (Cd)Diltiazem Hcl56$2,342
Carvedilol145$1,807
Midodrine Hcl30$1,805
Losartan Potassium138$1,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$219$332,484307 claims
Johnson & JohnsonXarelto$377$78,12479 claims
NovartisEntresto$596$66,03763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Teaneck

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →